Business Information
The group’s principal activities include identifying, developing and commercializing novel therapies. The products of the group include Zanaflex Capsules, Zanaflex, Fampridine-SR, Neuregulin Program, Remyelinating Antibody Program and Chondroitinase Program. The group products sold under the trade name Zanaflex(R). Customers served by the group include McKesson, Cardinal and Amerisource. Specific customer of the group is TMS Professional Markets Group, LLC. The group operates from the United States. The revenue of the group for the year 2006 was $27,351 (thousands).
|
|
Name |
Title
|
Email
|
| Ron Cohen | Dir., CEO, Pres. | N/A | | Andrew Blight | Chief Scientific Officer | N/A | | David Lawrence | CFO | N/A | | Mary Fisher | COO | N/A | | Denise Duca | Sr. VP - Human Resources | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 27,351 | (24,019) | | 2005 | 5,146 | (35,530) | | 2004 | N/A | (44,741)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
